Additive blockade of β2-integrin adhesion of eosinophils by salmeterol and fluticasone propionate Source: Eur Respir J 2004; 24: 333 Year: 2004
Inhibitory activity of mometasone furoate and dexamethasone on ICAM-1 expression and eotaxin, IL-6 and MCP-1 release by human foetal lung fibroblasts induced by TNF-α Source: Eur Respir J 2001; 18: Suppl. 33, 406s Year: 2001
Inhibitory activities of fluticasone propionate and salmeterol on airway epithelial cell functions (FLIC24): adhesion molecule expression and cytokine release Source: Eur Respir J 2001; 18: Suppl. 33, 246s Year: 2001
Additive blockade of β2-integrin adhesion of eosinophils by salmeterol and fluticasone propionate Source: Eur Respir J 2004; 23: 511-517 Year: 2004
Low doses of inhaled fluticasone propionate induce sputum eosinophil apoptosis and inhibit IL-5 release in naive symptomatic asthmatics (FLIC19) Source: Eur Respir J 2001; 18: Suppl. 33, 336s Year: 2001
Comparative effects of Mometason furoate and Zafirlukast in treatment of nasal polyps in asthmatic patients Source: Eur Respir J 2002; 20: Suppl. 38, 45s Year: 2002
A comparison of suplatast tosilate, a Th2 cytokine inhibitor, and inhaled fluticasone propionate for airway inflammation in mild asthma Source: Eur Respir J 2002; 20: Suppl. 38, 373s Year: 2002
Fluticasone furoate restores leptin/leptin receptor pathway in nasal epithelial cells Source: Annual Congress 2011 - Lung cell biology Year: 2011
Administration of mometasone furoate once daily in the evening is as effective as mometasone furoate administered twice daily in improving lung function in patients with mild to moderate persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 33s Year: 2003
Efficacy of mometasone furoate in patients with mild-to-moderate asthma: lack of gender-specific effects Source: Eur Respir J 2001; 18: Suppl. 33, 96s Year: 2001
Long-term effect of salmeterol and fluticasone propionate on β2 -integrin mediated adhesion of neutrophils: role of annexin-1 in COPD Source: Eur Respir J 2006; 28: Suppl. 50, 103s Year: 2006
Efficacy of fluticasone furoate (FF)/vilanterol (VI) or FF alone in asthma patients with differing eosinophil (eos) levels Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015
Synergistic inhibition of salmeterol with fluticasone propionate or rolipram on stimulated eosinophil binding of β2 -integrin to ICAM-1 and cytosolic gIV-phospholipase A2 activation Source: Eur Respir J 2003; 22: Suppl. 45, 455s Year: 2003
Multiple synergistic effects of fluticasone propionate and salmeterol on T-cell activation in bronchial asthma Source: Eur Respir J 2004; 24: Suppl. 48, 250s Year: 2004
Effect of beclomethasone dipropionate, formoterol and their combination on TNF-α-induced ICAM-1 and IL-8 expression in human bronchial epithelial cells Source: Annual Congress 2012 - Molecular biology of pro- and anti-inflammatory responses in the lung Year: 2012
Clinical efficacy of once-daily mometasone furoate in children with persistent asthma switched from treatment with fluticasone propionate Source: Annual Congress 2011 - Airways disease comorbidities and general aspects Year: 2011
Fluticasone furoate (FF): Prolonged duration of action compared with other ICS Source: Annual Congress 2010 - Regulation of airway pharmacology Year: 2010
Symptoms, induced sputum eosinophil percentages and treatment with salmeterol or fluticasone in mild asthmatics Source: Eur Respir J 2001; 18: Suppl. 33, 336s Year: 2001
Indacaterol acetate, glycopyrronium bromide, and mometasone furoate: effect on neuronal inflammation and acetylcholine release Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science Year: 2021
Indacaterol acetate, glycopyrronium bromide, and mometasone furoate: effect on human airway inflammation Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science Year: 2021